133 related articles for article (PubMed ID: 19776461)
21. Integrating health economics modeling in the product development cycle of medical devices: a Bayesian approach.
Vallejo-Torres L; Steuten LM; Buxton MJ; Girling AJ; Lilford RJ; Young T
Int J Technol Assess Health Care; 2008; 24(4):459-64. PubMed ID: 18828941
[TBL] [Abstract][Full Text] [Related]
22. The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis.
Skrepnek GH
Pharmacoeconomics; 2007; 25(8):649-64. PubMed ID: 17640107
[TBL] [Abstract][Full Text] [Related]
23. A Bayesian model averaging approach for cost-effectiveness analyses.
Conigliani C; Tancredi A
Health Econ; 2009 Jul; 18(7):807-21. PubMed ID: 18792078
[TBL] [Abstract][Full Text] [Related]
24. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
[TBL] [Abstract][Full Text] [Related]
25. A C++ program to calculate sample sizes for cost-effectiveness trials in a Bayesian framework.
Sarker SJ; Whitehead A; Khan I
Comput Methods Programs Biomed; 2013 Jun; 110(3):471-89. PubMed ID: 23399102
[TBL] [Abstract][Full Text] [Related]
26. A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy.
Favato G; Baio G; Capone A; Marcellusi A; Saverio Mennini F
Clin Ther; 2013 Jul; 35(7):904-14. PubMed ID: 23806328
[TBL] [Abstract][Full Text] [Related]
27. Modeling the value for money of changing clinical practice change: a stochastic application in diabetes care.
Hoomans T; Abrams KR; Ament AJ; Evers SM; Severens JL
Med Care; 2009 Oct; 47(10):1053-61. PubMed ID: 19648827
[TBL] [Abstract][Full Text] [Related]
28. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies.
Briggs AH; O'Brien BJ; Blackhouse G
Annu Rev Public Health; 2002; 23():377-401. PubMed ID: 11910068
[TBL] [Abstract][Full Text] [Related]
29. Bayesian assessment of sample size for clinical trials of cost-effectiveness.
O'Hagan A; Stevens JW
Med Decis Making; 2001; 21(3):219-30. PubMed ID: 11386629
[TBL] [Abstract][Full Text] [Related]
30. Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope.
Hoch JS; Rockx MA; Krahn AD
BMC Health Serv Res; 2006 Jun; 6():68. PubMed ID: 16756680
[TBL] [Abstract][Full Text] [Related]
31. Health technology assessment in the cost-disutility plane.
Eckermann S; Briggs A; Willan AR
Med Decis Making; 2008; 28(2):172-81. PubMed ID: 18356312
[TBL] [Abstract][Full Text] [Related]
32. Impact of generic drug entry on cost-effectiveness analysis.
Shih YC; Han S; Cantor SB
Med Decis Making; 2005; 25(1):71-80. PubMed ID: 15673583
[TBL] [Abstract][Full Text] [Related]
33. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
Allen D; Rixson L
Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
[TBL] [Abstract][Full Text] [Related]
34. Discounting and decision making in the economic evaluation of health-care technologies.
Claxton K; Paulden M; Gravelle H; Brouwer W; Culyer AJ
Health Econ; 2011 Jan; 20(1):2-15. PubMed ID: 21154521
[TBL] [Abstract][Full Text] [Related]
35. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI).
Barton GR; Briggs AH; Fenwick EA
Value Health; 2008; 11(5):886-97. PubMed ID: 18489513
[TBL] [Abstract][Full Text] [Related]
36. Bayesian estimation of cost-effectiveness: an importance-sampling approach.
Heitjan DF; Li H
Health Econ; 2004 Feb; 13(2):191-8. PubMed ID: 14737756
[TBL] [Abstract][Full Text] [Related]
37. Measuring and illustrating statistical evidence in a cost-effectiveness analysis.
Hoch JS; Blume JD
J Health Econ; 2008 Mar; 27(2):476-95. PubMed ID: 18179834
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness acceptability curves--caveats quantified.
Jakubczyk M; Kamiński B
Health Econ; 2010 Aug; 19(8):955-63. PubMed ID: 19688780
[TBL] [Abstract][Full Text] [Related]
39. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
Siebert U; Rochau U; Claxton K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
[TBL] [Abstract][Full Text] [Related]
40. Bayesian methods in meta-analysis and evidence synthesis.
Sutton AJ; Abrams KR
Stat Methods Med Res; 2001 Aug; 10(4):277-303. PubMed ID: 11491414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
